Abstract: | Intravenous donor antigen in the form of spleen cells can significantly potentiate the effects of ALS in prolonging the survival of skin allografts exchanged across both weak and strong histocompatibility barriers. This effect depends on the proper timing of antigen administration and can result in immunologic unresponsiveness of sufficient strength to permit acceptance of second set grafts. The skin allograft itself apparently plays a role in the establishment of this unresponsive state since ALS and antigen alone followed by delayed allografts at 21 days resulted in normal graft rejection times. |